Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Total Liabilities (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Total Liabilities for 3 consecutive years, with $138.5 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 193.51% to $138.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $138.5 million through Dec 2025, up 193.51% year-over-year, with the annual reading at $138.5 million for FY2025, 193.51% up from the prior year.
  • Total Liabilities for Q4 2025 was $138.5 million at Inhibrx Biosciences, down from $140.6 million in the prior quarter.
  • The five-year high for Total Liabilities was $264.4 million in Q4 2023, with the low at -$129.6 million in Q3 2023.
  • Average Total Liabilities over 3 years is $77.2 million, with a median of $47.2 million recorded in 2024.
  • The sharpest move saw Total Liabilities crashed 82.15% in 2024, then surged 1381.09% in 2025.
  • Over 3 years, Total Liabilities stood at $264.4 million in 2023, then plummeted by 82.15% to $47.2 million in 2024, then soared by 193.51% to $138.5 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $138.5 million, $140.6 million, and $143.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.